Participant Flow



Baseline characteristics by treatment group

		Offer of bandage group (n=489)	Rigid immobilisation group (n=476)
Age, years		9·61 (2·99)	9·69 (2·85)
Age range, years			
	4–7	153 (31%)	147 (31%)
	8–15	336 (69%)	329 (69%)
Sex			
	Female	179 (37%)	200 (42%)
	Male	310 (63%)	276 (58%)

Data are n (%) or mean (SD) unless indicated otherwise.

Primary Outcome: Day 3 Wong–Baker Scale, by treatment group

	Offer of bandage group (n=489)	**Rigid immobilisation group (n=476)**	**Effect size (95% CI)***	**p value**
Modified intention-to-treat analysis	3·21 (2·08); n=466	3·14 (2·11); n=442	–0·10 (–0·37 to 0·17)	
Per-protocol analysis	3·17 (2·04); n=428	3·14 (2·11); n=442	–0·06 (–0·34 to 0·21)	··
Other time points				
Day 0	5·21 (2·32)	4·91 (2·10)	··	··
Day 1	4·29 (2·25); n=408	3·94 (2·13); n=382	–0·36 (–0·61 to –0·12)	··
Day 3	3·21 (2·08); n=466	3·14 (2·11); n=442	–0·09 (–0·32 to 0·14)	··
Day 7	2·32 (1·81); n=459	2·12 (1·68); n=439	-0·21 (-0·44 to 0·02)	··
Day 21	0·81 (1·32); n=432	0·87 (1·39); n=429	0·04 (–0·20 to 0·27)	··
Day 42	0·27 (0·81); n=436	0·24 (0·77); n=431	–0·05 (–0·28 to 0·19)	··

Secondary outcomes by treatment group

	Offer of bandage group (n=489)	Rigid immobilisation group (n=476)	Effect size (95% CI)*	p value
PROMIS				
Baseline	25·0 (6·3) ; n=489	25·6 (7·7); n=476	..	..
Day 3	28·4 (7·8); n=462	27·8 (7·9); n=441	–0·50 (–1·58 to 0·57)	0·36
Day 7	34·7 (9·9); n=456	34·5 (9·2); n=437	–0·12 (–1·20 to 0·96)	0·82
Day 21	46·6 (10·1); n=431	46·3 (10·1); n=426	–0·26 (–1·36 to 0·83)	0·64
Day 42	52·8 (7·3); n=434	52·6 (7·5); n=428	–0·20 (–1·29 to 0·90)	0·72
EQ5DY-3L				
Baseline	0·53 (0·34); n= 489	0·56 (0·34); n=476	..	..
Day 3	0·56 (0·27); n=459	0·55 (0·27); n=441	–0·01 (–0·04 to 0·02)	0·43
Day 7	0·71 (0·23); n=456	0·69 (0·24); n=435	–0·01 (–0·04 to 0·02)	0·53
Day 21	0·89 (0·16); n=430	0·89 (0·16); n=426	–0·01 (–0·04 to 0·02)	0·65
Day 42	0·97 (0·10); n=434	0·96 (0·10); n=428	–0·00 (–0·04 to 0·03)	0·82
Satisfaction				
Day 1	2 (1, 2), 406	1 (1, 2), 380	..	<0·0001
Day 42	1 (1, 2), 433	1 (1, 2), 425	..	0·12
Use of any analgesia within the previous 24h				
Day 1	337/408 (83%)	297/382 (78%)	OR 0·53 (0·28 to 0·98)	0·04
Day 3	264/465 (57%)	227/442 (51%)	OR 0·60 (0·36 to 0·99)	0·05
Day 7	116/459 (25%)	100/439 (23%)	OR 0·70 (0·40 to 1·22)	0·21
School absence				
Participants who missed school	112/430 (26%)	93/425 (22%)	OR 0·79 (0·57 to 1·08)	0·14
Number of days of school missed	1·5 (1–2); n=112	1·5 (1–2); n=93	..	0·37
Any complication	5 (1·0%)	3 (0·6%)	..	..
Alternative fracture: greenstick	1 (0·2%)	1 (0·2%)	..	..
Alternative fracture: complete but remains undisplaced	3 (0·6%)	2 (0·4%)	..	..
Other	1 (0·2%)	0	..	..

Data are mean (SD), n/N (%), or median (IQR) unless otherwise indicated. Analyses are by intention to treat unless otherwise stated. PROMIS=Patient Report Outcomes Measurement System. EQ5DY-3L=child friendly EuroQol 3-level. OR=odds ratio.

* Effect sizes are adjusted difference, unless otherwise stated as OR

Adverse Events

There were no adverse events associated with this trial.